Immunoglobulin G1 (IgG1) is a subclass of immunoglobulin that plays a crucial role in the immune response, particularly in targeting specific antigens. The substance in question, anti-(human CD19), is a human monoclonal antibody designed to bind to the CD19 antigen, which is predominantly expressed on the surface of B cells. This characteristic makes it significant in therapeutic applications, especially in treating B-cell malignancies. The structure of this antibody includes a heavy chain and a kappa light chain, linked by disulfide bonds, which is typical for immunoglobulins, providing stability and functionality. As a dimer, it consists of two identical antibody units, enhancing its binding capacity and efficacy. The specificity for CD19 allows for targeted therapy, minimizing damage to non-cancerous cells. Overall, this compound exemplifies the advancements in monoclonal antibody technology, offering potential in precision medicine and immunotherapy.

Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer

1299440-37-1: Immunoglobulin G1 (IgG1) is a subclass of immunoglobulin that plays a crucial role in the immune response, particularly in targeting specific antigens. The substance in question, anti-(human CD19), is a human monoclonal antibody designed to bind to the CD19 antigen, which is predominantly expressed on the surface of B cells. This characteristic makes it significant in therapeutic applications, especially in treating B-cell malignancies. The structure of this antibody includes a heavy chain and a kappa light chain, linked by disulfide bonds, which is typical for immunoglobulins, providing stability and functionality. As a dimer, it consists of two identical antibody units, enhancing its binding capacity and efficacy. The specificity for CD19 allows for targeted therapy, minimizing damage to non-cancerous cells. Overall, this compound exemplifies the advancements in monoclonal antibody technology, offering potential in precision medicine and immunotherapy.

Inebilizumab: humanized anti-CD19 antibody, enhances cytotoxicity against B cells, treats autoimmune diseases like MS.

Inebilizumab

<p>Anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cell.</p>

CAS 1299440-37-1

Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer

Inebilizumab

Ref: TM-T76713

Inebilizumab

Ref: 3D-CLA1393